Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients:: a baseline-endpoint [123I]IBZM SPECT study

被引:28
作者
Bernardo, M [1 ]
Parellada, E
Lomeña, F
Catafau, AM
Font, M
Gómez, JC
López-Carrero, C
Gutiérrez, F
Pavía, J
Salamero, M
机构
[1] Univ Barcelona, IDIBAPS, Hosp Clin, Dept Psychiat,Serv Psiquiatria, Barcelona 08015, Spain
[2] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain
[3] Hosp St Pau, Nucl Med Serv, Barcelona, Spain
[4] Lilly SA, Dept Clin Res, Madrid, Spain
关键词
psychosis; benzamides; single photon emission computed tomography; olanzapine; D2 dopamine receptor;
D O I
10.1016/S0925-4927(01)00085-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The aim of this study was to compare in vivo striatal D2 dopamine receptor occupancy induced by olanzapine and haloperidol in schizophrenic patients using a baseline-endpoint [I-123]IBZM single photon computed emission tomography (SPECT) design. The relationships of striatal D2 receptor occupancy with clinical efficacy and extrapyramidal symptoms (EPS) were also assessed. Twenty-seven inpatients with schizophrenia or schizophreniform. disorder were included in a 4-week prospective, randomized, double-blind, parallel and comparative clinical trial. Thirteen patients were treated with haloperidol (10 mg/day) and 14 with olanzapine (10 mg/day). Ratings of clinical status and EPS were obtained weekly. The percentage of D2 receptor occupancy was estimated by using basal ganglia (striatum)/frontal cortex IBZM uptake ratios obtained from each patient before and after 4 weeks of maintained antipsychotic treatment. Olanzapine led to a mean striatal D2 receptor occupancy of 49% (range 28-69%), which was significantly lower than that induced by haloperidol (mean 64%, range 46-90%). The baseline-endpoint SPECT design used in this study revealed lower antipsychotic D2 occupancy percentage values than those reported in the literature, using other approaches. The degree of striatal D2 receptor occupancy correlated to the EPS, which predominantly appeared in patients on haloperidol. No relationship was found between the striatal D2 receptor occupancy and clinical improvement. Olanzapine induced a lower striatal D2 occupancy than haloperidol. This low striatal D2 occupancy, together with the lower incidence of EPS in olanzapine-treated patients, contributed to confirm the atypical behavior of this now antipsychotic drug. Nevertheless, conclusions based on SPECT-estimated percentages of antipsychotic D2 occupancy should be cautious, since the SPECT design could influence the results. In this regard, SPECT studies including baseline and endpoint examinations should be encouraged. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:87 / 97
页数:11
相关论文
共 42 条
[1]   A RATING-SCALE FOR DRUG-INDUCED AKATHISIA [J].
BARNES, TRE .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :672-676
[2]   In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs -: [123I]-epidepride single photon emission tomography (SPET) study [J].
Bigliani, V ;
Mulligan, RS ;
Acton, PD ;
Visvikis, D ;
Ell, PJ ;
Stephenson, C ;
Kerwin, RW ;
Pilowsky, LS .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 :231-238
[3]   Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo:: a [123I]epidepride single photon emission tomography (SPET) study [J].
Bigliani, V ;
Mulligan, RS ;
Acton, PD ;
Ohlsen, RI ;
Pike, VW ;
Ell, PJ ;
Gacinovic, S ;
Kerwin, RW ;
Pilowsky, LS .
PSYCHOPHARMACOLOGY, 2000, 150 (02) :132-140
[4]   DOPAMINE D-2 RECEPTOR BLOCKADE IN-VIVO WITH THE NOVEL ANTIPSYCHOTICS RISPERIDONE AND REMOXIPRIDE - AN I-123 IBZM SINGLE-PHOTON EMISSION TOMOGRAPHY (SPET) STUDY [J].
BUSATTO, GF ;
PILOWSKY, LS ;
COSTA, DC ;
ELL, PJ ;
VERHOEFF, NPLG ;
KERWIN, RW .
PSYCHOPHARMACOLOGY, 1995, 117 (01) :55-61
[5]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[6]  
FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538
[7]  
GUY W, 1976, PUBLICATION ECDEU NA
[8]  
Hall H, 1996, SYNAPSE, V23, P115, DOI 10.1002/(SICI)1098-2396(199606)23:2<115::AID-SYN7>3.0.CO
[9]  
2-C
[10]  
JARRITT PH, 1993, NEW TRENDS NUCL NEUR, P36